

廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

 $(a\ joint\ stock\ company\ with\ limited\ liability\ established\ in\ the\ People's\ Republic\ of\ China)$

(H Share Stock Code: 0874)

The number of shares to which

Proxy Form for the First Class Meeting of Holders of Domestic Shares in 2012

We Gooden 20 Of			this Proxy	Proxy Form relates (notes 1)			
sereby appoint the chairman of the Class Meeting of A Shareholders (as defined below) or Mr./Ms. (wites 3) st my/our proxy to attend and vote on my/our behalf at the first class meeting of holders of domestic shares in 2012 or any adjournment thereof Class Meeting of A Shareholders") of Gauagabou Pharmaceutical Company Limited (the "Company") to be held at 45 Sha Mian North Street, Li District, Guangzhou City, Guangdong Province, the People's Republic of China in the morning of Wednesday, 19 September 2012. Please indicate clearly your choice of "for", "against" or "abstain" for the following resolutions) Special Resolution The Resolution on the concurrent implementation of the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. through Share Swap of additional A shares and the Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited by Guangzhou Pharmaceutical Company Limited; The Resolution on the Proposal for the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Company Limited through Share Swap of Additional A Shares; The Resolution on the Proposal for the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; The Resolution on the Proposal for the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; All Valuation date 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement on	/Wa (n	otes 2)					
s my/our proxy to attend and vote on my/our behalf at the first class meeting of holders of domestic shares in 2012 or any adjournment thereof Class Meeting of A Shareholders") of Guangzhou Pharmaceutical Company Limited (the "Company") to be held at 45 Sha Mian North Street, Li Islatrict, Guangzhou City, Guangdong Province, the People's Republic of China in the morning of Wednesday, 19 September 2012. Please indicate clearly your choice of "for", "against" or "abstain" for the following resolutions) Special Resolution Special Resolution on the Concurrent implementation of the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. through Share Swap of additional A shares and the Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Company Limited; The Resolution on the Proposal for the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Company Limited; The Resolution on the Entering into and Implementation of the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; The Resolution on the Entering into and Implementation of the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; All Valuation of the Proposal for Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited on an item-by-item basis; 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement on Asset Acquis			(notes 3)				
Special Resolutions For (notes 4) Against (notes 4) Abstain (notes 4)	s my/ Class	our proxy to attend and vote on my/our behalf at the first class meeting of holders of dom Meeting of A Shareholders") of Guangzhou Pharmaceutical Company Limited (the "Comp	nestic share pany") to b	e held at 45	Sha Mian North	ent thereof (the n Street, Liwan	
1. The Resolution on the concurrent implementation of the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. through Share Swap of additional A shares and the Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited by Guangzhou Pharmaceutical Company Limited; 2. The Resolution on the Proposal for the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. by Guangzhou Pharmaceutical Company Limited through Share Swap of Additional A Shares; 3. The Resolution on the Entering into and Implementation of the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; 4. The Resolution on the Proposal for Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited on an item-by-item basis; 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	Please	e indicate clearly your choice of "for", "against" or "abstain" for the following resolutions)					
Baiyunshan Pharmaceutical Co., Ltd. through Share Swap of additional A shares and the Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited by Guangzhou Pharmaceutical Company Limited; 2. The Resolution on the Proposal for the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. by Guangzhou Pharmaceutical Company Limited through Share Swap of Additional A Shares; 3. The Resolution on the Entering into and Implementation of the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; 4. The Resolution on the Proposal for Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited on an item-by-item basis; 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement the Agreement on Asset Acquisition through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceuticial Holdings Limited;		Special Resolutions		For(notes 4)	Against(notes 4)	Abstain(notes 4)	
Pharmaceutical Co., Ltd. by Guangzhou Pharmaceutical Company Limited through Share Swap of Additional A Shares; 3. The Resolution on the Entering into and Implementation of the Absorption and Merger Agreement with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; 4. The Resolution on the Proposal for Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited on an item-by-item basis; 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement to the Agreement to Asset Acquisition Agreement to the Agreement to The Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	1.	Baiyunshan Pharmaceutical Co., Ltd. through Share Swap of additional A shares and th Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Lim	he Asset				
with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.; The Resolution on the Proposal for Asset Acquisition through Issuance of A Shares to Guangzhou Pharmaceutical Holdings Limited on an item-by-item basis; 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	2.	Pharmaceutical Co., Ltd. by Guangzhou Pharmaceutical Company Limited through Share					
Pharmaceutical Holdings Limited on an item-by-item basis; 4.1 Valuation date 4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	3.	with Guangzhou Baiyunshan Pharmaceutical Co., Ltd.;					
4.2 Nature of shares 4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	4.	The Resolution on the Proposal for Asset Acquisition through Issuance of A Shares to Gua Pharmaceutical Holdings Limited on an item-by-item basis;	angzhou				
4.3 Method of issue 4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	L	4.1 Valuation date					
4.4 Target subscriber and subscription method 4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.2 Nature of shares					
4.5 Value of the assets to be acquired 4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	L						
4.6 Number of shares to be issued 4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.4 Target subscriber and subscription method					
4.7 Issue price 4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.5 Value of the assets to be acquired					
4.8 Attribution of profit and loss from the assets to be acquired from the valuation date to the completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	Γ	4.6 Number of shares to be issued					
completion date 4.9 Lock-up period 4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.7 Issue price					
4.10 Place of listing 4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;			te to the				
4.11 Arrangement for accrued profit 4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.9 Lock-up period					
4.12 Validity of resolutions on the asset acquisition through issuance of shares 4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.10 Place of listing					
4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agreement 5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;	Γ	4.11 Arrangement for accrued profit					
5. The Resolution on the Entering into and Implementation of the Assets Acquisition Agreement through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.12 Validity of resolutions on the asset acquisition through issuance of shares					
through Issuance of Shares and the Supplemental Agreement to the Agreement on Asset Acquisition through Issuance of Shares with Guangzhou Pharmaceutical Holdings Limited;		4.13 Conditions precedent of the Asset Acquisition Agreement and its supplemental agree	ment				
6 The Developing on Entering into and Inglementation of the Agreement for the Componential of	5.	through Issuance of Shares and the Supplemental Agreement to the Agreement of	n Asset				
the Difference between Actual Earning and Net Earning Forecast of the Assets Proposed to be Acquired with Guangzhou Pharmaceutical Holdings Limited;	6.	The Resolution on Entering into and Implementation of the Agreement for the Compens the Difference between Actual Earning and Net Earning Forecast of the Assets Propose Acquired with Guangzhou Pharmaceutical Holdings Limited;	sation of ed to be				
7. The Resolution on the Report on the Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. through Share Swap, Asset Acquisition through Issuance of Shares and Connected Transactions of Guangzhou Pharmaceutical Company Limited (draft) published by the Company.	7.	Pharmaceutical Co., Ltd. through Share Swap, Asset Acquisition through Issuance of Sha Connected Transactions of Guangzhou Pharmaceutical Company Limited (draft) published	ares and				
Signature of Appointor (notes 5): Identity card number of Appointor:	Signati	ure of Appointor (notes 5): Identity card numbe	Identity card number of Appointor:				
Number of A shares held by Appointor (notes 6): Shareholder account number of appointor:	Numbe	er of A shares held by Appointor (notes 6): Shareholder account	Shareholder account number of appointor:				
Signature of Proxy (notes 5): Identity card number of Proxy:			**				
Date:, 2012			J .				

Notes:

- 1. Please insert the number of A shares registered in your name(s) and to which the proxy form relates. If no such number is inserted, this proxy form shall be deemed to be related to all the shares of the Company registered in your name(s).
- 2. Please write in block letters the full name(s) and address(es) as registered in the register of members.
- 3. If any person other than the chairman of the Class Meeting of A Shareholders is preferred, strike out "the chairman of the Class Meeting of A Shareholders or" and insert the full name(s) of proxy(ies) in the space provided in block letters. Shareholders may appoint one or more proxies to attend the Class Meeting of A Shareholders and to vote thereat. The proxy(ies) need(s) not be shareholder(s) of the Company. Any alteration made herein must be initialled by the signatory(ies).
- 4. Please note that if you would like to vote for any resolution, please put "X" in the "For" column. If you would like to vote against any resolution, please put "X" in the "Against" column. If you would like to abstain from any resolution, please put "X" in the "Abstain" column. If no instruction is given, the proxy(ies) is/are authorized to vote at his/her/their discretion.
- 5. This proxy form or other power of attorney must be duly signed by you or your attorney duly authorized in writing. If the appointor is a legal person, the proxy form shall be affixed with the seal of the legal person or signed by its director(s) or duly authorized representative(s). If the appointor is a joint holder, this proxy form shall be signed by the shareholder whose name stands first among such joint shareholders in the register of members.
- 6. Please insert the number of A shares registered in your name(s) and delete where inapplicable.
- 7. If this proxy form is signed by a person who is authorized by the appointor, the power of attorney or other authority under which it is signed must be notarized by a notary public. Such notarized power of attorney or other authority together with this proxy form must be deposited at the office address of the Company not less than 24 hours before the time appointed for the holding of the Class Meeting of A Shareholders in order to be valid.
- 8. This proxy form shall not preclude the appointor to attend the Class Meeting of A Shareholders in person and to vote thereat. In such event, the appointment of the original proxy(ies) will be void.